Takeuchi Hiromi, Yatsugi Shin-ichi, Yamaguchi Tokio
Neuroscience Research, Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Ibaraki, Japan.
Jpn J Pharmacol. 2002 Oct;90(2):197-200. doi: 10.1254/jjp.90.197.
YM992 ((S)-2-[[(7-fluoroindan-4-yl)oxy]methyl]morpholine) monohydrochloride is a novel antidepressant with selective serotonin (5-hydroxytryptamine, 5-HT) re-uptake inhibition and 5-HT(2A) receptor antagonistic activity. The effects of YM992 and two selective 5-HT re-uptake inhibitors (SSRIs) were studied in a marble-burying behavior test as a model of an obsessive-compulsive disorder (OCD) in mice at doses of 5, 10 and 15 mg/kg, i.p. YM992 and fluoxetine significantly inhibited marble-burying behavior at a dose of 15 mg/kg (i.p.) without affecting spontaneous locomotor activities. Citalopram also significantly inhibited the behavior at doses of 5, 10 and 15 mg/kg (i.p.) without affecting spontaneous locomotor activities. These results suggest that YM992, as well as SSRIs, may exhibit anti-OCD activity in addition to an antidepressive effect in clinical use.
盐酸 YM992（(S)-2-[[(7-氟茚满-4-基)氧基]甲基]吗啉）是一种新型抗抑郁药，具有选择性 5-羟色胺（5-羟色胺，5-HT）再摄取抑制作用和 5-HT(2A)受体拮抗活性。在小鼠强迫性神经症（OCD）模型的埋大理石行为试验中，研究了 YM992 和两种选择性 5-HT 再摄取抑制剂（SSRIs）在 5、10 和 15 mg/kg 腹腔注射剂量下的作用。YM992 和氟西汀在 15 mg/kg（腹腔注射）剂量下显著抑制埋大理石行为，且不影响自发运动活性。西酞普兰在 5、10 和 15 mg/kg（腹腔注射）剂量下也显著抑制该行为，且不影响自发运动活性。这些结果表明，YM992 以及 SSRIs 在临床应用中除具有抗抑郁作用外，可能还具有抗 OCD 活性。
